Alexander (Sasha) Kamb has almost 25 years of experience in the biotechnology sector, ranging from founder/CSO/CEO of a startup company to SVP and head of Amgen Discovery Research. Apart from drug discovery, he specializes in genetics, genomics, structural biology, neuroscience and oncology. He has published widely, including 13 peer-reviewed papers in The Cell, Science and Nature journals. Dr. Kamb received his AB from Harvard University and his PhD from Caltech. As a postdoctoral fellow at UCSF, Dr. Kamb invented an extremely rapid and broadly applicable method, using degenerate oligonucleotides coupled with DNA amplification, for cloning gene family members (Kamb et al., PNAS 1989).
After his postdoctoral training, Dr. Kamb joined Myriad Genetics, a startup company focused on identifying and commercializing human disease genes/diagnostics. He also founded a biotechnology company, Arcaris, specializing in somatic cell genetics. Afterwards, he joined Novartis as its global head of oncology. In this capacity he built the Cambridge (NIBR) oncology group. Dr. Kamb later became the senior vice president of Amgen’s entire Discovery Research organization. Dr. Kamb currently serves as chief scientific officer of a biotechnology company, A2 Biotherapeutics, focused on cancer and immune-mediated diseases.